INmune Bio (NASDAQ:INMB) Downgraded by Wall Street Zen to "Sell"

Key Points

• INmune Bio has been downgraded from a "hold" to a "sell" rating by Wall Street Zen, reflecting a bearish outlook from analysts.
• Maxim Group reduced their price target from $30.00 to $8.00 while maintaining a "buy" rating, indicating differing opinions among analysts about the stock's value.
• As of the latest reports, INmune Bio's stock price is $2.56, down 6.2%, with a market cap of $60.36 million and a negative P/E ratio of -1.33.

Wall Street Zen lowered shares of INmune Bio (NASDAQ:INMB - Free Report) from a hold rating to a sell rating in a report issued on Saturday.

A number of other analysts have also issued reports on INMB. Raymond James Financial lowered INmune Bio from a "moderate buy" rating to a "hold" rating in a research note on Monday, June 30th. Maxim Group cut their price target on INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, July 2nd. Scotiabank reaffirmed a "sector underperform" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Finally, BTIG Research restated a "neutral" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $18.40.

INmune Bio Stock Up 1.3%

Shares of INMB stock traded up $0.04 during mid-day trading on Friday, reaching $2.73. 834,786 shares of the company's stock traded hands, compared to its average volume of 1,610,009. INmune Bio has a 12 month low of $1.89 and a 12 month high of $11.64. The company has a market cap of $64.26 million, a P/E ratio of -1.42 and a beta of 0.97. The company's 50-day moving average price is $4.67 and its 200-day moving average price is $6.84.

INmune Bio (NASDAQ:INMB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The business had revenue of $0.05 million during the quarter. Equities analysts predict that INmune Bio will post -2.24 earnings per share for the current year.

Institutional Investors Weigh In On INmune Bio

Several institutional investors have recently made changes to their positions in INMB. PFG Investments LLC acquired a new position in INmune Bio during the second quarter worth $27,000. Wells Fargo & Company MN increased its position in INmune Bio by 51.0% during the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after buying an additional 2,155 shares during the last quarter. Modera Wealth Management LLC acquired a new position in INmune Bio during the second quarter worth $36,000. Beacon Pointe Advisors LLC acquired a new position in INmune Bio during the fourth quarter worth $48,000. Finally, Quarry LP acquired a new position in INmune Bio during the first quarter worth $48,000. 12.72% of the stock is currently owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.